Share Price | Lexeo Therapeutics, Inc. Stock Analysis & Recommendation

Q: How big is Lexeo Therapeutics, Inc.?

Market Cap: As of Jun 18, Lexeo Therapeutics, Inc. has a market capitalization of 130.24 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Lexeo Therapeutics, Inc. reported net sales of 0.00 million and a net profit of -109.31 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 116.84 million and total assets of 149.92 million.

Q: What does Lexeo Therapeutics, Inc. do?

Overview: Lexeo Therapeutics, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.Financial Snapshot: Net Profit: -33 Million (Quarterly Results - Mar 2025) Market Cap: USD 130.24 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.10 Return on Equity: -124.05% Price to Book: 1.48Contact Details: Details: No Company Details Available Registrar Address: Not available.

Q: Is Lexeo Therapeutics, Inc. technically bullish or bearish?

As of 5 September 2025, the technical trend for Lexeo Therapeutics, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and the monthly RSI is also bullish, indicating positive momentum. The daily moving averages are bullish, supporting the overall bullish stance. The Bollinger Bands show a bullish signal on the weekly timeframe, though they are mildly bearish on the monthly. The KST is bullish on the weekly, and the OBV is bullish for both weekly and monthly periods. Dow Theory indicates a mildly bullish trend on both weekly and monthly timeframes.In terms of performance, Lexeo has outperformed the S&P 500 over the past week and month, with returns of 5.41% and 10.98% respectively, compared to the S&P 500's 1.05% and 2.33%. However, year-to-date and one-year returns are significantly negative at -17.02% and -43.01%, respectively, compared to the S&P 500's positive returns of 12.22% and 17.14%. Overall, the current technical stance is bullish, driven by strong indicators across multiple timeframes.

Results Declared: Lexeo Therapeutics, Inc. has declared results on 30 Mar 2026! Click here to unlock the latest financial performance

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

386.56 k

Shareholding (Dec 2025)

FII

5.97%

Held by 50 FIIs

DII

62.2%

Held by 26 DIIs

Promoter

14.82%

How big is Lexeo Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Lexeo Therapeutics, Inc. has a market capitalization of 130.24 million, with net sales of 0.00 million and a net profit of -109.31 million over the last four quarters. The company reported shareholder's funds of 116.84 million and total assets of 149.92 million as of Dec 24.

View full answer

What does Lexeo Therapeutics, Inc. do?

22-Jun-2025

Lexeo Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $33 million and a market cap of $130.24 million. Key financial metrics include a negative P/E ratio, a 0.00% dividend yield, and a return on equity of -124.05%.

View full answer

Is Lexeo Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 5, 2025, Lexeo Therapeutics, Inc. shows a bullish technical trend with positive indicators across multiple timeframes, despite negative year-to-date and one-year returns compared to the S&P 500.

View full answer

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 480 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.99

Return on Equity

-86.87%

Price to Book

3.97

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

-21 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-42.9%

6 Months

-14.61%

1 Year

81.15%

2 Years

-64.23%

3 Years

0.0%

4 Years

0.0%

5 Years

0.0%

Lexeo Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-31.44%

EBIT Growth (5y)

-36.63%

EBIT to Interest (avg)

-94.40

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.10

Sales to Capital Employed (avg)

0.02

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

91.82%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

3.97

EV to EBIT

-3.17

EV to EBITDA

-3.23

EV to Capital Employed

359.66

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-11352.30%

ROE (Latest)

-86.87%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Sideways

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bearish

No Trend

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 27 Schemes (17.01%)

Foreign Institutions

Held by 50 Foreign Institutions (5.97%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 19.31% vs -82.39% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-22.60",
          "val2": "-26.90",
          "chgp": "15.99%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-20.90",
          "val2": "-25.90",
          "chgp": "19.31%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -1.73% vs -48.04% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-107.20",
          "val2": "-103.80",
          "chgp": "-3.28%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.10",
          "chgp": "100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-100.00",
          "val2": "-98.30",
          "chgp": "-1.73%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-22.60

-26.90

15.99%

Interest

0.10

0.00

Exceptional Items

0.00

Consolidate Net Profit

-20.90

-25.90

19.31%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is 19.31% vs -82.39% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-107.20

-103.80

-3.28%

Interest

0.20

0.10

100.00%

Exceptional Items

0.00

Consolidate Net Profit

-100.00

-98.30

-1.73%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -1.73% vs -48.04% in Dec 2024

All Annual Results

Company CV

About Lexeo Therapeutics, Inc.

Lexeo Therapeutics, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available